{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:18:43Z","timestamp":1787566723931,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08149-x","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:22:22Z","timestamp":1787559742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of [177Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3133-3134","authenticated-orcid":false,"given":"Dilsat Firat","family":"Arslan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-3501","authenticated-orcid":false,"given":"Caner","family":"Civan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6898","authenticated-orcid":false,"given":"Mehmet Oner","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6945-2003","authenticated-orcid":false,"given":"Duygu","family":"Has Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-5561","authenticated-orcid":false,"given":"Meltem","family":"Ekenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5437-134X","authenticated-orcid":false,"given":"Mert","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-1394","authenticated-orcid":false,"given":"Selcuk","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-6638","authenticated-orcid":false,"given":"Faruk","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1158-5361","authenticated-orcid":false,"given":"Serkan","family":"Kuyumcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-2379","authenticated-orcid":false,"given":"Yasemin","family":"Sanli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"8149_CR1","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1207506.","journal-title":"N Engl J Med"},{"key":"8149_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"key":"8149_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"key":"8149_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","volume":"48","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113\u201322. https:\/\/doi.org\/10.1007\/s00259-020-04797-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8149_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.euo.2018.11.007","volume":"2","author":"SP Thang","year":"2019","unstructured":"Thang SP, Violet J, Sandhu S, et al. Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) Expression deemed ineligible for lu-labelled PSMA radioligand therapy. Eur Urol Oncol. 2019;2:670\u201376. https:\/\/doi.org\/10.1016\/j.euo.2018.11.007.","journal-title":"Eur Urol Oncol"},{"key":"8149_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147431","volume":"22","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M, et al. Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci. 2021;22:7431. https:\/\/doi.org\/10.3390\/ijms22147431.","journal-title":"Int J Mol Sci"},{"key":"8149_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","volume":"47","author":"F Rosar","year":"2020","unstructured":"Rosar F, Dewes S, Ries M, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging. 2020;47:687\u201394. https:\/\/doi.org\/10.1007\/s00259-019-04674-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8149_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M, et al. Overall survival and quality of life with [(177)Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025;26:291\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9.","journal-title":"Lancet Oncol"},{"key":"8149_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"key":"8149_CR10","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1007\/s00259-025-07682-5","volume":"53","author":"F Rosar","year":"2026","unstructured":"Rosar F, Khreish F, Burgard C, et al. Comparison of mCRPC [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting. Eur J Nucl Med Mol Imaging. 2026;53:3034\u201341. https:\/\/doi.org\/10.1007\/s00259-025-07682-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8149_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.euo.2025.06.004","volume":"8","author":"M Muniz","year":"2025","unstructured":"Muniz M, Sartor O, Orme JJ, et al. Outcomes for [(177)Lu]Lu-PSMA-617 with and without concurrent use of androgen receptor pathway inhibitors in patients with metastatic castration-resistant prostate cancer. Eur Urol Oncol. 2025;8:1087\u201393. https:\/\/doi.org\/10.1016\/j.euo.2025.06.004.","journal-title":"Eur Urol Oncol"},{"key":"8149_CR12","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8149_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM\/SNMMI procedure guideline for the use of Lu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8149_CR14","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1200\/JCO-25-02834","volume":"44","author":"AJ Armstrong","year":"2026","unstructured":"Armstrong AJ, Morris MJ, Abida W, et al. Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4. J Clin Oncol. 2026;44:1249\u201365. https:\/\/doi.org\/10.1200\/JCO-25-02834.","journal-title":"J Clin Oncol"},{"key":"8149_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, et al. Nomograms to predict outcomes after Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"key":"8149_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS, et al. Multivariable models of outcomes with [(177)Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. EClinicalMedicine. 2024;77:102862. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102862.","journal-title":"EClinicalMedicine"},{"key":"8149_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.euo.2018.03.010","volume":"1","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Wei X, Kim W, et al. Heterogeneous flare in prostate-specific membrane antigen positron emission tomography tracer uptake with initiation of androgen pathway blockade in metastatic prostate cancer. Eur Urol Oncol. 2018;1:78\u201382. https:\/\/doi.org\/10.1016\/j.euo.2018.03.010.","journal-title":"Eur Urol Oncol"},{"key":"8149_CR18","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1007\/s00259-025-07178-2","volume":"52","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Farolfi A, Grogan T, et al. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2025;52:3700\u20138. https:\/\/doi.org\/10.1007\/s00259-025-07178-2.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08149-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T08:22:23Z","timestamp":1787559743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08149-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":18,"alternative-id":["8149"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08149-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the institutional ethics committee (approval no. 2026\/215).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any identifiable form.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for additional informed consent was waived by the institutional ethics committee due to the retrospective design and use of anonymized data.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each author certifies that there are no competing interests, including specific financial interests and relationships relevant to the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}